Other Corporate Information – Page 4

2023-10-05

Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy”

ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...

2023-09-28

Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...

2023-09-27

Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod ...

2023-08-21

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...

2023-08-17

Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the ...

2023-08-17

Lund, Sweden, August 17, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the resignation of Malin Carlsson as th ...

2023-08-15

Alligator Bioscience AB (publ) (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series TO 6 (the “warran ...

2023-07-31

Technical Feasibility achieved in second collaboration project triggering new milestone payment to Alligator Collaboration aims to discover ...

2023-07-11

Presentation highlights very promising interim efficacy analysis from mitazalimab OPTIMIZE-1 Phase 2 study in pancreatic cancer Latest analy ...